High-Throughput Mapping of SARS-CoV-2 Spike–ACE2 Compatibility

Study Background and Research Question

The specificity of viral entry is dictated by molecular recognition between viral surface proteins and host cell receptors. For SARS-CoV-2, the spike protein's interaction with the angiotensin-converting enzyme 2 (ACE2) receptor determines which species and cell types are susceptible to infection. However, as the spike protein accumulates mutations—particularly during the emergence of new variants—its compatibility with different ACE2 orthologs can shift, potentially enabling cross-species transmission events. Traditional experimental approaches have not allowed systematic, high-throughput assessment of how these viral and host sequence variations jointly affect infectivity. Addressing this technological gap, Shukla et al. set out to map how a panel of SARS-CoV-2 spike variants interact with a comprehensive library of ACE2 orthologs and human mutants, using an innovative multiplexed assay (Shukla et al., 2024).

Key Innovation from the Reference Study

The centerpiece of this work is the development of a scalable pseudotyped virus infection assay, in which target cells expressing different ACE2 variants are uniquely barcoded. This approach enables simultaneous, quantitative assessment of viral entry across dozens of ACE2 variants in a single experiment. By leveraging DNA barcode sequencing, the assay robustly measures infectivity for each spike–ACE2 pair, overcoming the throughput and scalability limitations of prior single-variant infection models. This multiplexed design allows comprehensive mapping of the combinatorial compatibility space between SARS-CoV-2 spike variants and diverse ACE2 receptors, directly informing understanding of zoonotic risk and viral adaptation.

Methods and Experimental Design Insights

Shukla et al. engineered a library of 30 ACE2 orthologs and human ACE2 mutants, each stably integrated into human target cells with a unique DNA barcode. The team produced lentiviral pseudoparticles, each bearing the spike protein from either the ancestral SARS-CoV-2 strain or one of five major variants of concern (Alpha, Beta, Gamma, Delta, Omicron BA.1). Infection assays were performed by exposing the multiplexed ACE2-expressing cell library to these pseudoviruses. Post-infection, barcode sequencing quantitated the relative infectivity for each ACE2 variant. Complementary structural analyses compared interface shifts induced by spike mutations, focusing on the N501Y substitution and others that alter ACE2 recognition. This integrated approach provided both functional and structural perspectives on spike–ACE2 compatibility.

Protocol Parameters

• ACE2 variant library construction: Stably integrate barcoded ACE2 ortholog/mutant cDNAs into the same host cell type to ensure uniform background.
• Pseudotyped virus production: Use lentiviral or retroviral particles, incorporating the spike protein variant of interest at the envelope.
• Infection conditions: Infect the multiplexed cell library at a controlled multiplicity of infection (MOI), ensuring barcodes remain uniquely traceable post-infection.
• Barcode sequencing and analysis: Extract genomic DNA after infection, PCR-amplify barcodes, and analyze relative abundance by next-generation sequencing.
• Structural analysis: Use available spike–ACE2 crystal structures or model interfaces to interpret functional shifts in light of observed infectivity patterns.

Core Findings and Why They Matter

The study found that while SARS-CoV-2 spike mutations had only modest effects on infectivity via human ACE2, they produced much larger shifts in compatibility with non-human ACE2 orthologs. Notably, the N501Y substitution—present in Alpha, Beta, Gamma, and Omicron BA.1, but not Delta—created a substantial structural shift at the spike–ACE2 interface, expanding the range of animal ACE2 variants that could support viral entry. Surprisingly, Delta's distinct substitutions partially recapitulated these effects via indirect mechanisms. Across 13 non-human ACE2 orthologs tested, 10 showed unique, variant-specific patterns of compatibility, demonstrating that spike evolution during human transmission can incrementally increase the virus's ability to infect a wider array of potential hosts. These results provide a mechanistic blueprint for understanding viral host range expansion and highlight the risk that continued spike evolution poses for future zoonotic spillover (Shukla et al., 2024).

Comparison with Existing Internal Articles

Internal resource summaries, such as "Multiplexed ACE2 Libraries Reveal SARS-CoV-2 Variant Adaptations", reinforce the significance of this high-throughput approach. These articles emphasize that systematic, barcoded infection assays illuminate the dynamic interplay between spike mutations and ACE2 diversity, offering unprecedented resolution into mechanisms of viral adaptation and cross-species risk. The current reference study substantially extends these insights by directly linking structural interface shifts to functional infectivity outcomes across a wide ACE2 variant spectrum.

Limitations and Transferability

Despite its strengths, the assay is restricted to in vitro systems using pseudotyped viruses, which do not capture the full complexity of authentic infection in vivo—including immune interactions, tissue tropism, and downstream replication steps. The ACE2 library, while comprehensive, cannot exhaustively represent all possible natural and engineered receptor variants. Finally, structural modeling relies on available spike–ACE2 complexes, which may not fully account for conformational flexibility. Nonetheless, the approach is highly transferable to other viral–receptor systems and provides a scalable blueprint for dissecting host range determinants in emerging pathogens.

Research Support Resources

To facilitate apoptosis pathway research and conditional cell ablation in engineered cell systems—such as those expressing barcoded receptors—researchers may employ chemical inducers of dimerization for controlled protein activation. AP1903 (SKU B4168), an FKBP-binding ligand available from APExBIO, enables precise modulation of FKBP fusion proteins and supports applications in apoptosis pathway modeling and targeted cell ablation. Its high potency (IC₅₀ 5 nM for F36V-FKBP) and compatibility with both in vitro and in vivo workflows are detailed in the existing literature. For those integrating controlled protein activation into multiplexed screening or conditional ablation platforms, AP1903 offers a robust, validated option. For protocol guidance, refer to product specifications and recent workflow-focused reviews.